Akèy › Leukemi › Tennessee › Nashville
Etid klinik pou Leukemi nan Nashville, TN
12 etid pou Leukemi ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Ap rekriteFaz 3
- Quetzal Site 12, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- TriStar BMT, Nashville
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- Vanderbilt University, Ingram Cancer Center, Nashville
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Ap rekriteFaz 2/3
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- TriStar Bone Marrow Transplant, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Nashville
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Ap rekriteFaz 1
- TriStar Bone Marrow Transplant, Nashville
Etid Leukemi nan lòt vil
- Houston, TX28 etid
- Boston, MA25 etid
- New York City, NY19 etid
- Los Angeles, CA16 etid
- Chicago, IL16 etid
- Durham, NC13 etid
- Baldwin Park, CA12 etid
- Columbus, OH12 etid
- Philadelphia, PA12 etid
- Milwaukee, WI11 etid
- Atlanta, GA11 etid
- Seattle, WA11 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete80 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat42 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.